Name | 6-(4-methoxyphenyl)-5-methyl-3-pyridin-4-yl-[1,2]oxazolo[4,5-c]pyridin-4-one |
---|---|
Synonyms |
S14-1930
Thioperamide 6-(4-Methoxyphenyl)-5-methyl-3-(4-pyridinyl)-isoxazolo[ 4,5-c]pyridin-4(5H)-one |
Description | MMPIP is an allosteric metabotropic glutamate receptor 7 (mGluR7) selective antagonist (KB values 24 -30 nM). MMPIP acts as a pharmacological tool for elucidating the roles of mGluR7 on central nervous system functions. MMPIP alleviates pain and normalizes affective and cognitive behavior in neuropathic mice[1][2]. |
---|---|
Related Catalog | |
Target |
mGlu7 |
In Vitro | MMPIP inhibits L-(+)-2-amino-4-phosphonobutyric acid (L-AP4; 0.5 mM)-induced intracellular Ca2+ mobilization in Chinese hamster ovary (CHO) cells coexpressing rat mGluR7 with Gα15 (IC50=26 nM) [1]. In CHO cells expressing rat mGluR7, MMPIP inhibits L-AP4-induced inhibition of forskolin-stimulated cAMP accumulation (IC0 220 nM)[1]. MMPIP also antagonizes L-AP4-induced inhibition of cAMP accumulation with an IC0 of 610 nM in CHO-human mGluR7/Gα15[1]. |
In Vivo | MMPIP (10 mg/kg) attenuates the amplitude of the acoustic startle response and markedly enhances the prepulse-induced inhibition of the acoustic startle response (up to 137% of control)[2]. MMPIP (10 mg/kg) rescues the MK-801 (0.1 mg/kg)-induced cognitive impairments, by improving the choice accuracy[2]. Zamifenacin exhibits short elimination half-lives (plasma 1.16, brain 1.75 h) following i.p. administration (10 mg/kg) in mice[2]. |
References |
Molecular Formula | C19H15N3O3 |
---|---|
Molecular Weight | 369.80200 |
Exact Mass | 369.08800 |
PSA | 70.15000 |
LogP | 4.06610 |
Symbol |
GHS06 |
---|---|
Signal Word | Danger |
Hazard Statements | H301 |
Precautionary Statements | P301 + P310 |
Hazard Codes | T+ |
RIDADR | UN 2811 6.1 / PGIII |